Prana launches Phase II study of Alzheimer's drug

03/6/2012 | ProactiveInvestors.co.au (Australia)

Prana Biotechnology has started with the first patient in a 12-month Phase II trial that will monitor levels of amyloid in the brain and assess cognitive and functional abilities in participants treated with PBT2, the company's investigational drug for Alzheimer's disease. Study participants will undergo PiB-PET imaging prior to treatment to determine starting amyloid levels.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA